Drug Trial Radar · NCT04817007
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Mar 22, 2021
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
Conditions
- Myelofibrosis
Interventions
BMS-986158Drug
Specified dose on specified days
RuxolitinibDrug
Specified dose on specified days
FedratinibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to 52 months
- Incidence of serious adverse events (SAEs)Time frame: Up to 52 months
- Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to 26 months
- Incidence of AEs leading to discontinuationTime frame: Up to 52 months
- Incidence of deathTime frame: Up to 52 months
Locations
49 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 0069
Newport Beach, California
Local Institution - 0090
Lake Mary, Florida
Local Institution - 0043
New Orleans, Louisiana
Local Institution - 0038
Worcester, Massachusetts
Local Institution - 0033
Ann Arbor, Michigan
Local Institution - 0045
Hackensack, New Jersey
Local Institution - 0076
Chapel Hill, North Carolina
Local Institution - 0042
Pittsburgh, Pennsylvania
Local Institution - 0036
Blacktown, New South Wales, Australia
Local Institution - 0032
Wollongong, New South Wales, Australia
Local Institution - 0007
East Melbourne, Victoria, Australia
Local Institution - 0006
Heidelberg, Victoria, Australia
Local Institution - 0041
Nedlands, Western Australia, Australia
Local Institution - 0015
West Perth, Western Australia, Australia
Local Institution - 0030
Brest, France
Local Institution - 0008
Marseille, France
Local Institution - 0027
Nice, France
Local Institution - 0011
Paris, France
Local Institution - 0010
Villejuif, France
Local Institution - 0068
Erding, Bavaria, Germany
Local Institution - 0039
Essen, North Rhine-Westphalia, Germany
Local Institution - 0040
Chemnitz, Saxony, Germany
Local Institution - 0035
Halle, Saxony-Anhalt, Germany
Local Institution - 0050
Lübeck, Schleswig-Holstein, Germany
Local Institution - 0061
Chaïdári, Attikí, Greece
Local Institution - 0047
Thessaloniki, Thessaloníki, Greece
Local Institution - 0016
Jerusalem, Israel
Local Institution - 0018
Petah Tikva, Israel
Local Institution - 0017
Ramat Gan, Israel
Local Institution - 0019
Tel Aviv, Israel
Local Institution - 0086
Beersheba, Southern District, Israel
Local Institution - 0003
Bologna, Italy
Local Institution - 0002
Brescia, Italy
Local Institution - 0001
Florence, Italy
Local Institution - 0012
Verona, Italy
Local Institution - 0062
Gdansk, Poland
Local Institution - 0077
Słupsk, Pomeranian Voivodeship, Poland
Local Institution - 0083
Bucharest, Romania
Local Institution - 0051
Cluj-Napoca, Romania
Local Institution - 0052
Bucuresti, Cluj, Romania
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.